Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin

NCT03094169 is registered in ClinicalTrials.gov with Formation Biologics as lead sponsor.

NCT NCT03094169
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03094169 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin
Lead sponsor
Formation Biologics
Phase
Phase 1/2
Overall status
Terminated
Start date
February 1, 2017
Completion date
January 30, 2021
Enrollment
49 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma, non small cell lung cancer, solid tumor, adult, triple negative breast cancer